Skip to content

G&A at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$14.61M+25.4%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$21.95M+31.4%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$13.44M-44.8%
Royalty Pharma logo
Royalty PharmaRPRX
$159.49M+44.1%
Enliven Therapeutics logo
Enliven TherapeuticsELVN
$7.14M+5.0%
Scholar Rock logo
Scholar RockSRRK
$50.2M+76.7%

Other financials

Income statement

See full
Revenue$26.5M+12,011%
Operating income-$13.3M+48.7%
Net income-$8.6M+59.8%
EPS (diluted)-$0.19+61.2%

Balance sheet

See full
Cash & equivalents$71.6M-65.9%
Total debt$23.1M-7.7%
Total equity$378.5M+195%
Total assets$569.7M+31.3%

Cash flow

See full
Operating cash flow-$25.6M-9.8%
CapEx$832.0K+118%
Free cash flow-$26.5M-11.5%

Valuation

See full
Market cap$1.65B+319%
Enterprise value$1.6B+1,325%
P/S22.8×-379×

Profitability

See full
Operating margin-77.1%-38.4pp
Net margin-49.9%-24.9pp
FCF margin467.9%+243pp

Returns & leverage

See full
Return on equity-12.2%
Debt / equity0.1×
Current ratio4.7×-27.5×

Where this comes from

Reported directly by Septerna, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Septerna, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Septerna, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Septerna, Inc.'s G&A?
Septerna, Inc. (SEPN) reported G&A of $10.29M in Q1 2026.
How has Septerna, Inc.'s G&A changed year-over-year?
Septerna, Inc.'s G&A increased by 50.0% year-over-year, from $6.86M to $10.29M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.